Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers

被引：14

作者：

Fujimura, Taku ^{[1
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 07期

关键词：

cancer stroma; TAMs; CAF; chemokines; angiogenetic factors; TUMOR-ASSOCIATED MACROPHAGES; BASAL-CELL CARCINOMA; LIGAND; EXPRESSION; REGULATORY T-CELLS; RECEPTOR ACTIVATOR; METASTATIC MELANOMA; SUPPRESSOR-CELLS; PERIOSTIN; LYMPHOMA; PAI-1;

D O I：

10.3390/ijms23074044

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1) antibodies (Abs) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) Abs, have been widely administered for not only advanced melanoma, but also various non-melanoma skin cancers. Since profiles of tumor-infiltrating leukocytes (TILs) play important roles in immunotherapy using ICIs, it is important to evaluate cancer stromal cells such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), as well as stromal extracellular matrix protein, to predict the efficacy of ICIs. This review article focuses particularly on TAMs and related factors. Among TILs, TAMs and their related factors could be the optimal biomarkers for immunotherapy such as anti-PD1 Ab therapy. According to the studies presented, TAM-targeting therapies for advanced melanoma and non-melanoma skin cancer will develop in the future.

引用

页数：14

共 106 条

[1] The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities [J].

Amor, Nadia Ghinelli ;

da Silva Santos, Paulo Sergio ;

Campanelli, Ana Paula .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9

[2]

Amor Nadia Ghinelli, 2018, Oncotarget, V9, P30894, DOI 10.18632/oncotarget.25768

[3] Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases [J].

Angela, Yenny ;

Haferkamp, Sebastian ;

Weishaupt, Carsten ;

Ugurel, Selma ;

Becker, Juergen C. ;

Oberndoerfer, Florian ;

Alar, Vesna ;

Satzger, Imke ;

Gutzmer, Ralf .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) :1187-1194

[4] Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib [J].

Atzori, Maria Grazia ;

Ceci, Claudia ;

Ruffini, Federica ;

Trapani, Mauro ;

Barbaccia, Maria Luisa ;

Tentori, Lucio ;

D'Atri, Stefania ;

Lacal, Pedro Miguel ;

Graziani, Grazia .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (01) :465-475

[5] Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma [J].

Berestjuk, Ilona ;

Lecacheur, Margaux ;

Carminati, Alexandrine ;

Diazzi, Serena ;

Rovera, Christopher ;

Prod'homme, Virginie ;

Ohanna, Mickael ;

Popovic, Ana ;

Mallavialle, Aude ;

Larbret, Frederic ;

Pisano, Sabrina ;

Audebert, Stephane ;

Passeron, Thierry ;

Gaggioli, Cedric ;

Girard, Christophe A. ;

Deckert, Marcel ;

Tartare-Deckert, Sophie .

EMBO MOLECULAR MEDICINE, 2022, 14 (02)

[6] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma [J].

Blank, Christian U. ;

Rozeman, Elisa A. ;

Fanchi, Lorenzo F. ;

Sikorska, Karolina ;

van de Wiel, Bart ;

Kvistborg, Pia ;

Krijgsman, Oscar ;

van den Braber, Marlous ;

Philips, Daisy ;

Broeks, Annegien ;

van Thienen, Johannes, V ;

Mallo, Henk A. ;

Adriaansz, Sandra ;

ter Meulens, Sylvia ;

Pronk, Loes M. ;

Grijpink-Ongering, Lindsay G. ;

Bruining, Annemarie ;

Gittelman, Rachel M. ;

Warren, Sarah ;

van Tinteren, Harm ;

Peeper, Daniel S. ;

Haanen, John B. A. G. ;

van Akkooi, Alexander C. J. ;

Schumacher, Ton N. .

NATURE MEDICINE, 2018, 24 (11) :1655-+

[7]

Boutsikas G, 2017, J BUON, V22, P1022

[8] Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial [J].

Carlino, Matteo S. ;

Long, Georgina V. ;

Schadendorf, Dirk ;

Robert, Caroline ;

Ribas, Antoni ;

Richtig, Erika ;

Nyakas, Marta ;

Caglevic, Christian ;

Tarhini, Ahmed ;

Blank, Christian ;

Hoeller, Christoph ;

Bar-Sela, Gil ;

Barrow, Catherine ;

Wolter, Pascal ;

Zhou, Honghong ;

Emancipator, Kenneth ;

Jensen, Erin H. ;

Ebbinghaus, Scot ;

Ibrahim, Nageatte ;

Daud, Adil .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :236-243

[9] IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis [J].

Coffelt, Seth B. ;

Kersten, Kelly ;

Doornebal, Chris W. ;

Weiden, Jorieke ;

Vrijland, Kim ;

Hau, Cheei-Sing ;

Verstegen, Niels J. M. ;

Ciampricotti, Metamia ;

Hawinkels, Lukas J. A. C. ;

Jonkers, Jos ;

de Visser, Karin E. .

NATURE, 2015, 522 (7556) :345-+

[10] Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up [J].

D'Angelo, S. P. ;

Bhatia, S. ;

Brohl, A. S. ;

Hamid, O. ;

Mehnert, J. M. ;

Terheyden, P. ;

Shih, K. C. ;

Brownell, I ;

Lebbe, C. ;

Lewis, K. D. ;

Linette, G. P. ;

Milella, M. ;

Xiong, H. ;

Guezel, G. ;

Nghiem, P. T. .

ESMO OPEN, 2021, 6 (06)

← 1 2 3 4 5 6 7 8 9 10 →